Researchers conducted a retrospective cohort study to assess the predictive value of molecular profiling on thyroid tumor behavior.

PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer; higher CD163-positive TAMs are linked to better outcomes.